DrugPatentWatch Database Preview
Drugs in Development Information for DEBIO-1347
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for DEBIO-1347?
DEBIO-1347 is an investigational drug.
There have been 20 clinical trials for DEBIO-1347.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2007.
The most common disease conditions in clinical trials are Bacterial Infections, Hepatitis C, Chronic, and Infection. The leading clinical trial sponsors are Debiopharm International SA, INC Research, and Parexel.
Summary for DEBIO-1347
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 5 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2007-09-01) |
| Vendors | 36 |
Recent Clinical Trials for DEBIO-1347
| Title | Sponsor | Phase |
|---|---|---|
| Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors | Debiopharm International SA | Phase 1 |
| Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 | Debiopharm International SA | Phase 1/Phase 2 |
| Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma | Debiopharm International SA | Phase 1 |
Clinical Trial Summary for DEBIO-1347
Top disease conditions for DEBIO-1347
Top clinical trial sponsors for DEBIO-1347
US Patents for DEBIO-1347
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
